Traditional & Natural Health Alliance
Published by Anthony Rees · June 18 at 12:38pm

REGULATORY TRENDS - Here in South Africa our drug regulator the Medicines Control Council / SAHPRA have a backlog of over 7 900 new novel and generic drugs, and a historical backlog of over 9 000 'old medicines' or 'grandfathered medicines' which have never been assessed for their safety and efficacy, yet been allowed to be sold on the market for decades. Considerable pressure from the pharmaceutical industry has resulted in the MCC / SAHPRA following a similar approach to the US Food and Drug Administration (FDA) with creating fast-track systems for drugs to be approved.
In clinical practice, so dangerous has the pharma approach to medicine now become that orthodox doctors, hospitals and their treatments have been shown in the Journal of the American Medical Association (JAMA) to be the third leading cause of death in the United States [1], exceeded only by deaths from heart disease and cancer. Providing further evidence of just how large the problem now is, a JAMA study published in 1998 estimated that in 1994 around 2,216,000 hospitalised patients in the United States had suffered a serious adverse drug reaction (ADR) and that 106,000 suffered a fatal ADR. [2]
These statistics illustrate why we urgently have to replace the profit-oriented pharmaceutical business with disease [3] with a system of healthcare that is based on safe, preventive, natural approaches. The economic wealth that will be created through significantly reducing the incidence of diseases – and by creating an effective, sustainable and prevention-oriented health care system on a global scale – will be unprecedented. Huge amounts of money will become available to address the burning issues of mankind, including mass unemployment, environmental protection and support for economic and social advances in the developing world.
But this quantum leap forward for mankind will not come by itself – we need to work together to organize it!


Popular posts from this blog

Misconduct in the Pharmaceutical Sector - Novartis

Corruption in the Pharmaceutical Trade - BAYER AG

Misconduct in the Pharmaceutical trade - GlaxoSmithKline